Use of daratumumab in first-line therapy for multiple myeloma
https://doi.org/10.36604/1998-5029-2026-100-145-155
Abstract
Introduction. Multiple myeloma (MM) is one of the most common hematologic malignancies.
Aim. To demonstrate the potential of using the targeted monoclonal antibody daratumumab in patients with newly diagnosed MM.
Materials and methods. Two clinical cases illustrating the efficacy and safety of daratumumab-based regimens in newly diagnosed MM are presented.
Results. Both patients received first-line therapy including daratumumab. The first patient was treated according to the Dara-Vd protocol (daratumumab, bortezomib, dexamethasone), while the second received Dara-Rd (daratumumab, lenalidomide, dexamethasone). The choice of regimen was guided by baseline disease status and the presence of osteolytic bone lesions. Both patients achieved a partial response, followed by autologous stem cell transplantation (aHSCT). Subsequently, consolidation therapy with daratumumab-containing protocols was administered, resulting in complete remission of MM.
Conclusion. These clinical cases illustrate the high efficacy of daratumumab in first-line treatment of MM in aHSCT-eligible patients and the possibility of achieving a response after 3–6 cycles of therapy.
About the Authors
V. V. Voytsekhovskiy
Amur State Medical Academy
Russian Federation
Russian Federation
Valeriy V. Voytsekhovskiy, MD, DSc (Med.), Professor, Head of Department of Hospital Therapy with Pharmacology Course named after Professor Yu.S. Landyshev
95 Gor'kogo Str., Blagoveshchensk, 675000
T. V. Еsenina
Amur Regional Clinical Hospital
Russian Federation
Russian Federation
Tatiana V. Еsenina, MD, Head of Department of Hematology
26 Voronkova Str., Blagoveshchensk, 675028
E. A. Filatova
Amur Regional Clinical Hospital
Russian Federation
Russian Federation
Ekaterina A. Filatova, MD, PhD (Med.), Hematologist of Department of Hematology
26 Voronkova Str., Blagoveshchensk, 675028
N. А. Fedorova
Amur Regional Clinical Hospital
Russian Federation
Russian Federation
Natalia А. Fedorova, MD, Hematologist of Department of Hematology
26 Voronkova Str., Blagoveshchensk, 675028
I. A. Kornilovich
Amur State Medical Academy
Russian Federation
Russian Federation
Iuliia A. Kornilovich, 6th year Student
95 Gor'kogo Str., Blagoveshchensk, 675000
V. R. Shelestova
Amur State Medical Academy
Russian Federation
Russian Federation
Valeria R. Shelestova, 6th year Student
95 Gor'kogo Str., Blagoveshchensk, 675000
E. I. Beliaeva
Amur State Medical Academy
Russian Federation
Russian Federation
Ekaterina I. Beliaeva, 6th year Student
95 Gor'kogo Str., Blagoveshchensk, 675000
K. Zh. Saidova
Amur State Medical Academy
Russian Federation
Russian Federation
Kamila Zh. Saidova, 6th year Student
95 Gor'kogo Str., Blagoveshchensk, 675000
S. V. Ishchenko
Amur State Medical Academy
Russian Federation
Russian Federation
Sergey V. Ishchenko, 6th year Student
95 Gor'kogo Str., Blagoveshchensk, 675000
Yu. N. Glyzina
Amur State Medical Academy
Russian Federation
Russian Federation
Yulia N. Glyzina, 6th year Student
95 Gor'kogo Str., Blagoveshchensk, 675000
T. V. Sheshera
Amur State Medical Academy
Russian Federation
Russian Federation
Taisiia V. Sheshera, 6th year Student
95 Gor'kogo Str., Blagoveshchensk, 675000
V. A. Bogdanovich
Amur State Medical Academy
Russian Federation
Russian Federation
Vladislav A. Bogdanovich, 6th year Student
95 Gor'kogo Str., Blagoveshchensk, 675000
V. S. Strelnikova
Amur State Medical Academy
Russian Federation
Russian Federation
Vlada S. Strelnikova, 6th year Student
95 Gor'kogo Str., Blagoveshchensk, 675000
I. S. Kuznetsov
Amur State Medical Academy
Russian Federation
Russian Federation
Ilia S. Kuznetsov, 6th year Student
95 Gor'kogo Str., Blagoveshchensk, 675000
References
1. Mendeleeva L.P., Votiakova O.M., Rekhtina I.G., Osmanov E.A., Poddubnaya I.V., Grivtsova L.I., Falaleeva N.A., Baikov V.V., Kovrigina A.M., Nevol’skikh A.A., Ivanov S.A., Khailova Z.V., Gevorkian T.G. [Multiple myeloma. Clinical recommendations]. Sovremennaya onkologiya = Journal of Modern Oncology 2020; 22(4):6–28 (in Russian). https://doi.org/10.26442/18151434.2020.4.200457
2. Ulumbekova G.E., Petrachkov I.V. [Oncohematological diseases in the Russian Federation and developed countries: mortality, morbidity, resources and organization of medical care in the context of the COVID-19 pandemic]. ORGZDRAV: novosti, mneniya, obuchenie. Vestnik VSHOUZ = HEALTHCARE MANAGEMENT: News, Views, Education. Bulletin of VSHOUZ 2022; 8(2):22–47 (in Russian). https://doi.org/10.33029/2411-8621-2022-8-2-22-47
3. Semochkin S.V., Mitina T.A., Zeinalova P.A., Ryzhko V.V., Smirnova S.Yu., Klyueva E.A., Fedorova L.V., Uspenskaya O.S., Shuvaev V.A., Lomaia E.G. [Retrospective analysis of treatment approaches for patients with first relapses of multiple myeloma in Russia]. Klinicheskaya onkogematologiya. Fundamental'nye issledovaniya i klinicheskaya praktika = Clinical Oncohematology. Fundamental Research and Clinical Practice 2024; 17(S2):21–23 (in Russian). https://doi.org/10.21320/2500-2139-2024-17-S2-21-23
4. Lokhorst H.M., Plesner T., Laubach J.P., Nahi H., Gimsing P., Hansson M., Minnema M.C., Lassen U., Krejcik J., Palumbo A., van de Donk N.W.C.J., Ahmadi T., Khan I., Uhlar C.M., Wang J., Sasser A.K., Losic N., Lisby S., Basse L., Brun N., Richardson P.G. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N. Engl. J. Med. 2015; 373(13):1207–1219. https://doi.org/10.1056/NEJMoa1506348
5. Lonial S., Dimopoulos M., Palumbo A., White D., Grosicki S., Spicka I., Walter-Croneck A., Moreau P., Mateos M.V., Magen H., Belch A., Reece D., Beksac M., Spencer A., Oakervee H., Orlowski R.Z., Taniwaki M., Röllig C., Einsele H., Wu K.L., Singhal A., San-Miguel J., Matsumoto M., Katz J., Bleickardt E., Poulart V., Anderson K.C., Richardson P. Elotuzumab therapy for relapsed or refractory multiple myeloma. N. Engl. J. Med. 2015; 373(7):621–631. https://doi.org/10.1056/NEJMoa1505654
6. Dimopoulos M.A., Oriol A., Nahi H., San-Miguel J., Bahlis N.J., Usmani S.Z., Rabin N., Orlowski R.Z., Komarnicki M., Suzuki K., Plesner T., Yoon S.S., Ben Yehuda D., Richardson P.G., Goldschmidt H., Reece D., Lisby S., Khokhar N.Z., O’Rourke L., Chiu C., Qin X., Guckert M., Ahmadi T., Moreau P. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N. Engl. J. Med. 2016; 375(14):1319–1331. https://doi.org/10.1056/NEJMoa1607751
7. Palumbo A., Chanan-Khan A., Weisel K., Nooka A.K., Masszi T., Beksac M., Spicka I., Hungria V., Munder M., Mateos M.V., Mark T.M., Qi M., Schecter J., Amin H., Qin X., Deraedt W., Ahmadi T., Spencer A., Sonneveld P. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N. Engl. J. Med. 2016; 375(8):754–766. https://doi.org/10.1056/NEJMoa1606038
8. Mateos M.V., Dimopoulos M.A., Cavo M., Suzuki K., Jakubowiak A., Knop S., Doyen C., Lucio P., Nagy Z., Kaplan P., Pour L., Cook G., Grosicki S., Crepaldi A., Liberati A.M., Campbell P., Shelef T., Yoon S.S., Iosava G., Fujisaki T., Garg M., Chiu C., Wang J., Carson R., Crist W., Deraedt W., Nguyen H., Qi M., San-Miguel J. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N. Engl. J. Med. 2018; 378(6):518–528. https://doi.org/10.1056/NEJMoa1714678
9. Facon T., Kumar S., Plesner T., Orlowski R.Z., Moreau P., Bahlis N., Basu S., Nahi H., Hulin C., Quach H., Goldschmidt H., O’Gorman P., Perrot A., Touzeau C., Patterson M., Shustik C., Casneuf T., Chiu C., Qin X., Sasser K., San-Miguel J., Richardson P.G. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N. Engl. J. Med. 2019; 380(22):2104–2115. https://doi.org/10.1056/NEJMoa1817249
10. Moreau P., Attal M., Hulin C., Arnulf B., Belhadj K., Benboubker L., Béné M.C., Broijl A., Caillon H., Caillot D., Corre J., Delforge M., Dejoie T., Doyen C., Facon T., Fontan J., Garderet L., Jaccard A., Karlin L., Leleu X., Macro M., Malfuson J.V., Orsini-Piocelle F., Roussel M., Salwender H., Scheid C., Stoppa A.M., van de Velde H., van de Donk N.W.C.J., Wuilleme S., Zweegman S., Kolb B., Michallet M., Avet-Loiseau H. Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 trial. Lancet 2019; 394(10197):29–38. https://doi.org/10.1016/S0140-6736(19)31240-1
11. Voorhees P.M., Kaufman J.L., Laubach J., Sborov D.W., Reeves B., Rodriguez C., Chari A., Silbermann R., Costa L.J., Anderson L.D. Jr., Nathwani N., Shah N., Efebera Y.A., Holstein S.A., Costello C., Jakubowiak A., Wildes T.M., Orlowski R.Z., Shain K.H., Cowan A.J., Murphy S., Lutska Y., Pei H., Ukropec J., Vermeulen J., de Boer C., Hoehn D., Lin T.S., Richardson P.G. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN study. Blood 2020; 136(8):936–945. https://doi.org/10.1182/blood.2020005288
12. Sonneveld P., Dimopoulos M.A., Boccadoro M., Quach H., Ho P.J., Beksac M., Hulin C., Antonioli E., Leleu X., Mangiacavalli S., Perrot A., Cavo M., Belotti A., Broijl A., Gay F., Mina R., Nijhof I.S., van de Donk N.W.C.J., Katodritou E., Schjesvold F., Sureda Balari A., Rosiñol L., Delforge M., Roeloffzen W., Silzle T., Vangsted A., Einsele H., Spencer A., Hajek R., Jurczyszyn A., Lonergan S., Ahmadi T., Liu Y., Wang J., Vieyra D., van Brummelen E.M.J., Vanquickelberghe V., Sitthi-Amorn A., de Boer C.J., Carson R., Rodriguez-Otero P., Bladé J., Moreau P.; PERSEUS Trial Investigators. Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N. Engl. J. Med. 2024; 390(4):301–313. https://doi.org/10.1056/NEJMoa2312054
13. Mateos M.V., Nahi H., Legiec W., Grosicki S., Vorobyev V., Spicka I., Hungria V., Korenkova S., Bahlis N., Flogegard M., Bladé J., Moreau P., Kaiser M., Iida S., Laubach J., Magen H., Cavo M., Hulin C., White D., De Stefano V., Clemens P.L., Masterson T., Lantz K., O'Rourke L., Heuck C., Qin X., Parasrampuria D.A., Yuan Z., Xu S., Qi M., Usmani S.Z. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial. Lancet Haematol. 2020; 7(5):e370–e380. doi: 10.1016/S2352-3026(20)30070-3. Erratum in: Lancet Haematol. 2020; 7(10):e710. doi: 10.1016/S2352-3026(20)30296-9
14. Nijhof I.S., Casneuf T., van Velzen J., van Kessel B., Axel A.E., Syed K., Groen R.W.J., van Duin M., Sonneveld P., Minnema M.C., Zweegman S., Chiu C., Bloem A.C., Mutis T., Lokhorst H.M., Sasser A.K., van de Donk N.W.C.J. CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma. Blood 2016; 128(7):959–970. https://doi.org/10.1182/blood-2016-03-703439
15. Lawrence L. Teclistamab plus daratumumab significantly boosts survival for patients with early RRMM. Cancer 2026; 132:e70299. https://doi.org/10.1002/cncr.70299
16. Marvel D., Choudhary G., Song Q., Kurupati R., Portale J., Suraneni M., Vishwamitra D., Brayer J., Hein N., Wang X., Lendvai N., Schecter J.M., Bartlett J.B., Plaks V. Preclinical analysis of ciltacabtagene autoleucel combination strategies with t cell bispecifics and daratumumab to support optimization of clinical benefit in myeloma patients. Blood 2024; 144(Suppl.1):7167. https://doi.org/10.1182/blood-2024-211334
17. Semochkin S.V. [Functional cure as a new concept of multiple myeloma therapy]. Klinicheskaya onkogematologiya. Fundamental'nye issledovaniya i klinicheskaya praktika = Clinical Oncohematology. Fundamental Research and Clinical Practice 2025; 18(2):105–120 (in Russian). https://doi.org/10.21320/2500-2139-2025-18-2-105-120
18. Durie B.G.M., Salmon S.E. A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975; 36(3):842–854. https://doi.org/10.1002/1097-0142(197509)36:3<842::aid-cncr2820360303>3.0.co;2-u
19. Greipp P.R., San Miguel J., Durie B.G.M., Crowley J.J., Barlogie B., Bladé J., Boccadoro M., Child J.A., Avet-Loiseau H., Kyle R.A., Lahuerta J.J., Ludwig H., Morgan G., Powles R., Shimizu K., Shustik C., Sonneveld P., Tosi P., Turesson I., Westin J. International staging system for multiple myeloma. J. Clin. Oncol. 2005; 23(15):3412–3420. https://doi.org/10.1200/JCO.2005.04.242
20. Kumar S., Paiva B., Anderson K.C., Durie B., Landgren O., Moreau P., Munshi N., Lonial S., Bladé J., Mateos M.V., Dimopoulos M., Kastritis E., Boccadoro M., Orlowski R., Goldschmidt H., Spencer A., Hou J., Chng W.J., Usmani S.Z., Zamagni E., Shimizu K., Jagannath S., Johnsen H.E., Terpos E., Reiman A., Kyle R.A., Sonneveld P., Richardson P.G., McCarthy P., Ludwig H., Chen W., Cavo M., Harousseau J.L., Lentzsch S., Hillengass J., Palumbo A., Orfao A., Rajkumar S.V., Miguel J.S., Avet-Loiseau H. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016; 17(8):e328–e346. https://doi.org/10.1016/S1470-2045(16)30206-6
Review
For citations:
Voytsekhovskiy V.V., Еsenina T.V., Filatova E.A., Fedorova N.А., Kornilovich I.A., Shelestova V.R., Beliaeva E.I., Saidova K.Zh., Ishchenko S.V., Glyzina Yu.N., Sheshera T.V., Bogdanovich V.A., Strelnikova V.S., Kuznetsov I.S. Use of daratumumab in first-line therapy for multiple myeloma. Bulletin Physiology and Pathology of Respiration. 2026;(100):145-155. (In Russ.) https://doi.org/10.36604/1998-5029-2026-100-145-155
Views:
57
JATS XML
Email this article 